These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33772987)

  • 21. Efficacy and Safety of Intravenous rtPA in Ischemic Strokes Due to Small-Vessel Occlusion: Systematic Review and Meta-Analysis.
    Karaszewski B; Wyszomirski A; Jabłoński B; Werring DJ; Tomaka D
    Transl Stroke Res; 2021 Jun; 12(3):406-415. PubMed ID: 33641037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of the Telestroke Drip-And-Stay Model: A Systematic Review and Meta-Analysis.
    Waseem H; Salih YA; Burney CP; Abel MA; Riblet N; Kim A; Robbins N
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105638. PubMed ID: 33540336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous Thrombolysis Increases the Rate of Dramatic Recovery in Patients with Acute Stroke with an Unknown Onset Time and Negative FLAIR MRI.
    Aoki J; Sakamoto Y; Kimura K
    J Neuroimaging; 2016 Jul; 26(4):414-9. PubMed ID: 27388586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA.
    Shah K; Clark A; Desai SM; Jadhav AP
    Neurocrit Care; 2022 Feb; 36(1):123-129. PubMed ID: 34228264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
    Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms.
    Urrutia VC; Faigle R; Zeiler SR; Marsh EB; Bahouth M; Cerdan Trevino M; Dearborn J; Leigh R; Rice S; Lane K; Saheed M; Hill P; Llinas RH
    PLoS One; 2018; 13(5):e0197714. PubMed ID: 29787575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
    Mowla A; Memon A; Razavi SM; Lail NS; Vaughn CB; Mohammadi P; Sawyer RN; Shirani P
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105678. PubMed ID: 33640783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes with Alteplase at 0.6 mg/kg in Clinical Practice: THAWS2 Study.
    Yoshimura S; Koga M; Okada T; Inoue M; Miwa K; Fukuda-Doi M; Kondo R; Inoue T; Ichijo M; Ohtaki M; Nagakane Y; Itabashi R; Sakai N; Kimura K; Kamiyama K; Shiokawa Y; Yagita Y; Iwama T; Yakushiji Y; Kusumi M; Yamaki T; Uemura J; Yasuura A; Noshiro S; Fukunaga D; Yazawa Y; Aoki J; Yoshikawa M; Ihara M; Toyoda K;
    Cerebrovasc Dis; 2024; 53(1):46-53. PubMed ID: 37263235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanical Thrombectomy and Intravenous Thrombolysis in Patients with Acute Stroke: A Systematic Review and Network Meta-Analysis.
    Matsumoto S; Mikami T; Iwagami M; Briasoulis A; Ikeda T; Takagi H; Kuno T
    J Stroke Cerebrovasc Dis; 2022 Jul; 31(7):106491. PubMed ID: 35468495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenously administered tissue plasminogen activator useful in milder strokes? A meta-analysis.
    Yeo LLL; Ho R; Paliwal P; Rathakrishnan R; Sharma VK
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2156-2162. PubMed ID: 25113080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant Tissue-Type Plasminogen Activator Study of Wake-Up Ischemic Strokes Guided by Rapid MRI.
    Guo C; Bai Q; Zhao Z; Zhang J
    Cerebrovasc Dis; 2019; 48(1-2):85-90. PubMed ID: 31587000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.
    Roveri L; La Gioia S; Ghidinelli C; Anzalone N; De Filippis C; Comi G
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):703-8. PubMed ID: 22133742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual antiplatelet therapy versus intravenous tissue plasminogen activator with acute minor ischemic stroke: A systematic review and meta-analysis of safety and efficacy.
    Abbas A; Hamad AA; El Din Moawad MH; Ewis DK; Youssef RA; Hamouda H; Hassan MA; Aladawi M; Elfil M; Meshref M; Al-Mufti F
    J Stroke Cerebrovasc Dis; 2024 Jul; 33(7):107704. PubMed ID: 38561167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. About 30% of wake-up stroke patients may be candidate for the tPA therapy using Negative-FLAIR as a "tissue clock".
    Nagai K; Aoki J; Sakamoto Y; Kimura K
    J Neurol Sci; 2017 Nov; 382():101-104. PubMed ID: 29110999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
    Nisar T; Hanumanthu R; Khandelwal P
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104360. PubMed ID: 31501036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
    Adeoye O; Sucharew H; Khoury J; Vagal A; Schmit PA; Ewing I; Levine SR; Demel S; Eckerle B; Katz B; Kleindorfer D; Stettler B; Woo D; Khatri P; Broderick JP; Pancioli AM
    Stroke; 2015 Sep; 46(9):2529-33. PubMed ID: 26243231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
    Marsh EB; Gottesman RF; Hillis AE; Urrutia VC; Llinas RH
    Medicine (Baltimore); 2013 Nov; 92(6):317-323. PubMed ID: 24145699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.